Is UNII-502FWN4Q32 Safe in Breastfeeding
Question
I am a breastfeeding mother and i want to know if it is safe to use UNII-502FWN4Q32? Is UNII-502FWN4Q32 safe for nursing mother and child? Does UNII-502FWN4Q32 extracts into breast milk? Does UNII-502FWN4Q32 has any long term or short term side effects on infants? Can UNII-502FWN4Q32 influence milk supply or can UNII-502FWN4Q32 decrease milk supply in lactating mothers?
UNII-502FWN4Q32 lactation summary
- DrLact safety Score for UNII-502FWN4Q32 is 3 out of 8 which is considered Low Risk as per our analyses.
- A safety Score of 3 indicates that usage of UNII-502FWN4Q32 may cause some minor side effects in breastfed baby.
- Our study of different scientific research indicates that UNII-502FWN4Q32 may cause moderate to no side effects in lactating mother.
- Most of scientific studies and research papers declaring usage of UNII-502FWN4Q32 low risk in breastfeeding are based on normal dosage and may not hold true for higher dosage.
- While using UNII-502FWN4Q32 We suggest monitoring child for possible reactions. It is also important to understand that side effects vary largely based on age of breastfed child and time of medication in addition to dosage.
- Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.
Answer by Dr. Ru: About UNII-502FWN4Q32 usage in lactation
At latest update, relevant information on excretion into breast milk was not found. Because of pharmacokinetic data (wide distribution volume and moderately high molecular weight) excretion into breast milk in significant quantity seems to be unlikely. Based on a low oral bioavailability, concentration in the infant's plasma should be nil or low, except in premature and newborn infants with a increased intestinal absorption capacity.
Alternate Drugs for Anti-hypertensive Angiotensin II receptor antagonists. ATC C09C
Eprosartan(Low Risk)
Irbesartan(Unsafe)
Losartan(Low Risk)
Telmisartan(Unsafe)
Valsartan(Low Risk)
Aliskiren(Low Risk)
Candesartan Cilexetil(Low Risk)
Losartan Potassium(Low Risk)
Olmesartan Medoxomil(Low Risk)
CS-866(Low Risk)